Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session
Name
Amrik Singh, PhD
Title
Senior Fellow, Immunology - Cell Signaling Technology
Bio
Novel Monoclonal Antibodies for the Characterization of CAR-Engineered Immune Cells
07:50 - 08:10 PDT / 10:50 - 11:10 EDT / 15:50 - 16:10 BST
Dr. Amrik Singh is a Senior Fellow in Immunology at Cell Signaling Technology (CST), where he leverages over 16 years of industry experience to advance early-stage drug discovery, assay development, and molecular biology workflows. A deeply technical scientist, Dr. Singh has broad expertise across cancer biology and signal transduction pathways—specifically relating to cell growth, proliferation, and apoptosis. Prior to joining CST, Dr. Singh completed his doctoral research at the Boston University School of Medicine, focusing on angiogenic signal relay via VEGFR-2 , followed by a postdoctoral research fellowship at BIDMC/Harvard Medical School studying the molecular mechanisms of oncogenic protein kinases and transcription factors. At CST, he works at the intersection of high-quality antibody development and advanced translational applications to provide researchers with robust, highly reproducible quantitative tools with a focus on developing antibodies and assays to enable cell therapy research.
07:50 - 08:10 PDT / 10:50 - 11:10 EDT / 15:50 - 16:10 BST
Dr. Amrik Singh is a Senior Fellow in Immunology at Cell Signaling Technology (CST), where he leverages over 16 years of industry experience to advance early-stage drug discovery, assay development, and molecular biology workflows. A deeply technical scientist, Dr. Singh has broad expertise across cancer biology and signal transduction pathways—specifically relating to cell growth, proliferation, and apoptosis. Prior to joining CST, Dr. Singh completed his doctoral research at the Boston University School of Medicine, focusing on angiogenic signal relay via VEGFR-2 , followed by a postdoctoral research fellowship at BIDMC/Harvard Medical School studying the molecular mechanisms of oncogenic protein kinases and transcription factors. At CST, he works at the intersection of high-quality antibody development and advanced translational applications to provide researchers with robust, highly reproducible quantitative tools with a focus on developing antibodies and assays to enable cell therapy research.
